Protein kinase C (PKC) isoforms transduce myriad signals within the cell in response to the generation of second messengers from membrane phospholipids. The conventional isozyme PKCγ reversibly binds Ca2+ and diacylglycerol, which leads to an open, active conformation. PKCγ expression is typically restricted to neurons, but evidence for its expression in certain cancers has emerged. PKC isoforms have been labeled as oncogenes since the discovery that they bind tumor-promoting phorbol esters, however, studies of cancer-associated PKC mutations and clinical trial data showing that PKC inhibitors have worsened patient survival have reframed PKC as a tumor suppressor. Aberrant expression of PKCγ in certain cancers suggests a role outside the brain, although whether PKCγ also acts as a tumor suppressor remains to be established. On the other hand, PKCγ variants associated with spinocerebellar ataxia type 14 (SCA14), a neurodegenerative disorder characterized by Purkinje cell degeneration, enhance basal activity while preventing phorbol ester-mediated degradation. Although the basis for SCA14 Purkinje cell degeneration remains unknown, studies have revealed how altered PKCγ activity rewires cerebellar signaling to drive SCA14. Importantly, enhanced basal activity of SCA14-associated mutants inversely correlates with age of onset, supporting that enhanced PKCγ activity drives SCA14. Thus, PKCγ activity should likely be inhibited in SCA14, whereas restoring PKC activity should be the goal in cancer therapies. This review describes how PKCγ activity can be lost or gained in disease and the overarching need for a PKC structure as a powerful tool to predict the effect of PKCγ mutations in disease.

Keywords: protein kinase C, autoinhibition, spinocerebellar ataxia, cancer, neurodegeneration

INTRODUCTION

The protein kinase C (PKC) branch of the AGC kinase family tree is encoded by nine genes to yield 10 isoforms. These share a similar primary sequence and 3D architecture, yet are differentially regulated by second messengers to transduce a diverse range of signals within the cell. The conventional PKC isoforms (α, βI/II, and γ) are the most well-characterized, with signaling of these isoforms being tightly restricted to ensure activation only in response to appropriate stimuli.
maintain the enzyme in an inactive conformation. The DG-sensing C1 domains and Ca\textsuperscript{2+}-sensing C2 domain pack against the kinase domain to maintain it in an autoinhibited conformation (Antal et al., 2015a). Binding of DG and Ca\textsuperscript{2+} permits pseudosubstrate release from the active site and substrate phosphorylation. These second messengers are generated upon receptor-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP\textsubscript{2}) into DG and IP\textsubscript{3}, which causes Ca\textsuperscript{2+} release into the cytosol. Binding of Ca\textsuperscript{2+} to the C2 domain leads to plasma membrane engagement and PIP\textsubscript{2} binding (Evans et al., 2006). At the plasma membrane, the C1B domain binds DG, and the C1A domain assists in pseudosubstrate release from the active site (Antal et al., 2014). Second messenger metabolism leads to a decrease in PKC activity due to re-autoinhibition.

To gain this autoinhibited state, newly-translated PKC undergoes a series of priming phosphorylations involving mammalian target of rapamycin (mTOR) complex 2 (mTORC2), pyruvate dehydrogenase kinase 1 (PDK-1), and autophosphorylation (Baffi and Newton, 2022). Autophosphorylation at the C-terminal hydrophobic motif is necessary for PKC to adopt the autoinhibited conformation (Baffi et al., 2019). PKC that is not properly autoinhibited is dephosphorylated by the PH domain and leucine rich repeat protein phosphatase (PHLPP), and subsequently shunted to a degradative pathway (Baffi et al., 2019). This PHLPP-mediated dephosphorylation of PKC acts as a quality control mechanism, ensuring that only properly autoinhibited PKC accumulates in the cell. For example, cancer-associated PKC mutants that impair PKC autoinhibition, including cancer fusion proteins, are paradoxically loss-of-function because mutant protein is degraded by this quality control pathway (Baffi et al., 2019; Van et al., 2021). In this way, prolonged activation promotes the dephosphorylation and degradation of PKC. Additionally, tumor-promoting phorbol esters, which lock PKC in an open and active conformation, lead to dephosphorylation and degradation of PKC (Hansra et al., 1999). Thus, phorbol esters lead to acute activation, but ultimately downregulation, of PKC (Jaken et al., 1981).

**PKC Isozymes Share a Common 3D Architecture**

PKC isozymes share similar domain composition, including a regulatory N-terminal region, a hinge region, and a C-terminal kinase domain (Figure 1A). Contained within the regulatory N-terminal moiety, the pseudosubstrate region binds within the kinase domain active site pocket and prevents signaling in the absence of appropriate second messengers. The regulatory C1 domains bind diacylglycerol (DG) with varying affinity depending on the isozyme class (conventional, novel, or atypical), and they contribute to maintaining PKC in an autoinhibited conformation (Newton, 2018). The C1 domains also serve as docking sites for PHLPP and are required for PHLPP-mediated quality control of PKC (Gao et al., 2008). The C2 domain packs against the kinase domain to keep the pseudosubstrate in the active site pocket until, in conventional PKC isozymes, it binds Ca\textsuperscript{2+} and allows PKC to engage with PIP\textsubscript{2} at the plasma membrane (Antal et al., 2015a).

Although PKC domain structures have been solved, the full-length structure and the 3D architecture of PKC has yet to be fully elucidated. A partial crystal structure of PKC\textbeta II was previously solved, however multiple domains remained unresolved due to inadequate electron density (Leonard et al., 2011). Refining this structure, Leonard and others concluded that conventional and novel PKC isozymes share a common 3D architecture,

---

**FIGURE 1** | Domain composition and structural model of PKC\textgamma. (A) Primary structure of PKC\textgamma, including the pseudosubstrate (PS, red), C1A and C1B (orange), C2 (yellow), kinase (cyan), and C-tail (black line). Circles indicate the priming phosphorylation sites: activation loop (pink), turn motif (orange) and hydrophobic motif (green). This structure is conserved amongst conventional PKCs with a noteworthy difference is a short Pro-rich extension of the C-tail for PKC\textgamma. (B) Domain architecture of conventional PKCs with domains labeled. Arrows indicate linker direction. (C) Hypothetical model of PKC\textgamma structure based on the previously published model for general architecture of PKC isozymes (Jones et al., 2020; Pilo et al., 2022), showing kinase domain as cyan surface, and the C1 domains and C2 domains in ribbon representation. SCA14 mutations, represented as red spheres, are concentrated in C1B domain or interfaces with the kinase domain.
demonstrating that conserved clamps pack the C1 and C2 domains against the kinase domain (Lučić et al., 2016). In this study, the authors found that mutating certain residues of the PKCβII C2 domain led to faster translocation, suggesting that these residues make up a C2-kinase domain interface (Lučić et al., 2016). A study by Antal et al. mutated lysine residues on the same face of the C2 domain that led to increased translocation of PKCβII (Antal et al., 2015a). Putting the pieces together from these biochemical studies, Kornev and others proposed a conventional and novel PKC structural model (Jones et al., 2020) (Figure 1B). Because the N- and C-termini of each regulatory domain are in close proximity, the authors hypothesized that the regulatory domains would be “plugged in” to the kinase domain to form a common 3D architecture. This hypothetical structure provides a framework upon which other PKC isoforms can be modeled. In the context of PKCy, for which no structure has yet been solved, this hypothetical structure allows for modeling of disease-associated mutations and predictions for how these mutations would affect PKCy biochemistry (Figure 1C).

The C-tail of AGC kinases acts to modulate catalysis and to mediate regulatory protein interactions (Kannan et al., 2008). The C-tail wraps around the kinase to structure the enzyme, enables ATP binding, and assists in substrate engagement (Kannan et al., 2008). In PKC isoforms, C-tail phosphorylation at the turn motif and hydrophobic motif is critical for kinase stability (Baffi et al., 2019). PDK-1 docks on the C-tail of PKC to phosphorylate the activation loop (Gao et al., 2001). The C-tail also serves as a docking site for peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (Pin1), which regulates PKC downregulation (Abrahamsen et al., 2012), heat shock protein 90 (Hsp90) and cell division cycle 37, Hsp90 co-chaperone (Cdc37), which mediate PKC maturation through the C-tail PxxP motif (Gould et al., 2009), and mTORC2, which phosphorylates PKC at the turn motif and mTOR-interacting motif (TIM) (Cameron et al., 2011; Baffi et al., 2021). In solution, the isolated C-tail is intrinsically disordered, but adopts a helical structure with mixed micelles, as the C-tail tethers PKC to membranes during maturation (Yang and Igumenova, 2013). The C-tail is also one of the most variable regions between PKC isoforms, which is likely critical for determining isoform specificity, given the high sequence similarity in other domains between isoforms (Yang and Igumenova, 2013). PKCy is particularly interesting in this regard, exhibiting the longest C-terminal tail of the conventional isoforms with an approximately 20 amino acid extension over that of PKCa and βII. The C-tail of PKCy is particularly proline-rich, with the C-terminal extension additionally containing a PVPVPV repeat. This region has yet to be fully characterized, but this proline-rich region likely mediates protein-protein interactions with PKCy, such as those involving DGK isoforms (Houssa et al., 1997; Yamaguchi et al., 2006).

**PKCy in Cancer**

In the 1980s, Nishizuka and others discovered that PKC isoforms are the receptor for the tumor-promoting phorbol esters (Castagna et al., 1982), which formed the basis of the dogma that PKC isoforms act as oncogenes. Inhibitors for PKC were developed for treatment of various cancers, yet in clinical trials, they were not only ineffective in treating cancer, but worsened patient outcome. Indeed, a clinical trial meta-analysis for non-small cell lung cancer showed that PKC inhibitors combined with chemotherapy worsened patient outcomes compared with chemotherapy alone (Zhang et al., 2015). A comprehensive study of cancer-associated mutations in every PKC isozyme revealed that PKC mutations in cancer are generally loss-of-function (Antal et al., 2015b). Furthermore, high levels of PKC protein are associated with improved survival in diverse cancers (Tovell and Newton, 2021), reframing PKC as having tumor suppressive properties. Although phorbol esters acutely activate PKC, they lead to the long-term loss of the kinase, so their tumor-promoting properties may arise from their downregulation of PKC (Newton and Brognard, 2017). Thus, restoring PKC function may be a more promising therapeutic avenue for cancer therapy.

Typically, PKCy is only expressed in neuronal cell types, particularly in the cerebral cortex, hippocampus, and cerebellum (Saito et al., 1988; Saito and Shirai, 2002; Gomis-González et al., 2021). However, evidence for aberrant PKCy expression has been established in certain cancer types, such as colon cancer and breast cancer (Parsons and Adams, 2008; Gargarczyczk et al., 2010; Dowling et al., 2017; Alloathaim et al., 2021). Although the mechanism that triggers anomalous PKCy expression in cancer remains unclear, several studies have addressed the role of PKCy in these cell types. Specifically, Kiely and others demonstrated that PKCy knockdown in colon cancer cell lines HT-29 and HCT-116 inhibited cell migration and growth in 2D and 3D (Dowling et al., 2017). However, the HCT-116 cell line contains mutations in PKCy (Barretina et al., 2012; Nusinow et al., 2020), suggesting that growth inhibition may have arisen from knockdown of a mutated PKCy. Additionally, PKCy has been found to be expressed and stabilized in several colon cancer cell lines with the addition of butyrate – a short-chain fatty acid present in the colon at millimolar concentrations (Gargarczyczk et al., 2010). Parsons and Adams elucidated a possible mechanism by which aberrantly expressed PKCy may promote colon cancer cell migration, showing that PKCy interacted with the tumor-promoting fascin (Parsons and Adams, 2008). On the other hand, in the context of triple negative breast cancer (TNBC), PKCy has been shown to promote HDAC6 inhibitor-mediated lethality of non-mesenchymal TNBC (Alloathaim et al., 2021). Thus, some studies have led to the conclusion that PKC promotes growth, but other factors, like mutations in PKCy, have not been accounted for.

Mutant PKC has been previously found to have a dominant-negative effect on other PKC isoforms by preventing their processing by phosphorylation, likely because processing requires common titratable elements (Garcia-Paramio et al., 1998). Indeed, many colon cancer cell lines express unphosphorylated PKCy that is only phosphorylated when butyrate is present, suggesting that mutated PKCy may act in a dominant-negative manner in these cells (Gargarczyczk et al., 2010). Furthermore, short-term treatment with PKCy CIB
domain peptides decreases anchorage-independent growth in the colon cancer cell line COLO205, while increasing expression of other PKC isozymes and p53 (Kawabata et al., 2012). Longer treatment with these peptides decreases PKCα and p53 expression (Kawabata et al., 2012). Thus, mutant PKCy that is not properly processed and autoinhibited, may lead to global PKC downregulation. Thus, in further studies on the role of PKCy in cancer, it will be critical to address the effects of PKCy mutations and how they may be affecting other PKC isozymes.

PKCy in Ataxia

Aberrant PKCy also drives the pathology of a subtype of spinocerebellar ataxia (SCA). SCAs consist of a group of approximately 40 subtypes, all of which are characterized by cerebellar atrophy caused by Purkinje cell (PC) degeneration, resulting in loss of motor coordination and control (Sun et al., 2016). Each SCA subtype is caused by variants in different genes, thus, diagnosis with a specific SCA subtype requires genomic sequencing. Variants in the gene encoding PKCy (PRKCG) are associated with SCA subtype 14 (SCA14) approximately 20 years ago (Yamashita et al., 2000; Chen et al., 2003; Tabe et al., 2003). To date, approximately 50 variants in PKCy have been identified as causative for SCA14, with most mutations occurring in the CIA and CIB domains (Adachi et al., 2008; Wong et al., 2018; Shirafuji et al., 2019; Schmitz-Hübsch et al., 2021).

The role of aberrant PKCy in SCA14 has been the subject of much investigation over the past two decades. Early studies established a clear role of PKC activation in PC degeneration. Specifically, studies with organotypic slice cultures from mouse cerebellum showed that phorbol ester treatment leads to PC dendrite degeneration, whereas PKC inhibition leads to an increased dendrite formation and decreased apoptosis (Ghoumari et al., 2002; Schrenk et al., 2002). How PKC activation causes this degeneration remains to be established. However, unbiased network analyses and mechanistic studies provide important clues. One commonality between SCA subtypes may be altered synaptic signaling involving PKCy, as suggested by network analyses by Verbeek and others (Nibbeling et al., 2017). There is evidence to suggest that this altered signaling may involve diacylglycerol kinase γ (DGKγ). Importantly, PKCy regulates DGKγ via phosphorylation, enabling DGKγ to metabolize DG into phosphatidic acid (Yamaguchi et al., 2006). Specifically, DGKγ knockout mice exhibited PC dendrite degeneration, which was reversed by conventional PKC inhibition (Tsumagari et al., 2020). These mice also exhibited impaired long-term depression (LTD), a critical process in synaptic plasticity. Notably, LTD is known to be induced by PKCα (Leitges et al., 2004), but not PKCy (Chen et al., 1995). Thus, mutant PKCy may reduce PKCα function, and therefore LTD induction, via decreased cellular DG. Corroborating this, one study found impaired LTD induction and a decrease in depolarization-induced PKCα membrane residence time in PCs expressing a SCA14-associated mutant PKCy, S119P (Shuvaev et al., 2011). Although PKCy may drive SCA14 by other mechanisms, these studies suggest that enhanced PKCy activity drives SCA14 in a DGK-dependent manner.

How the diverse SCA14 mutations alter PKC function has also been the subject of numerous studies culminating in a recent comprehensive analysis of approximately 50 variants (Pilo et al., 2022). This study concluded that ataxia-associated PKCy mutations enhance basal activity, as mutations in each domain of PKCy had impaired autoinhibition (Pilo et al., 2022). Although defects in autoinhibition generally lead to PKC degradation, this study demonstrated that CIA domain mutations protect PKCy from phorbol ester-induced downregulation. Additionally, the degree of impaired autoinhibition correlated inversely with average age of disease onset in patients, supporting a role for disrupted PKCy autoinhibition in SCA14 (Pilo et al., 2022). A previous study of SCA14-associated PKCy mutations demonstrated that SCA14-associated mutations unmasked the CIA domains to increase PKCy membrane translocation (Verbeek et al., 2005, 2008), using a genetically-encoded PKC activity reporter (Violin et al., 2003), the authors showed reduced amplitude of agonist-evoked activation of PKCy SCA14 mutations leading the authors to suggest that the SCA14 mutations had impaired activity. However, basal activity was not addressed in this study, and later analysis showed that basal activity, rather than agonist-induced activity drives SCA14 (Pilo et al., 2022). Another study expressing various SCA14-associated mutants in PCs in vitro demonstrated no effect of the mutants on dendritic development, concluding that enhanced activity of PKCy was not required for SCA14 pathogenesis (Shimobayashi and Kapfhammer, 2017). Studies on G360S, a variant occurring in the kinase domain of PKCy, have also produced conflicting reports. Whereas Adachi et al. found that this mutant is not activated by Ca²⁺ (Adachi et al., 2008), Ueno and others demonstrated that G360S was more basally active and had higher agonist-stimulated activity compared to wild-type PKCy (Asai et al., 2009). A mutant that generates an early stop in the CIA domain of PKCy (R76X) leads to elimination of PKCy activity, however, this fragment may activate other PKC isozymes via RACKs (Shirafuji et al., 2019). Aggregation of PKCy mutants in SCA14 has also been a focus within the field. Specifically, overexpression studies of wild-type and mutant PKCy have been shown to form toxic fibrils and aggregates, the occurrence of which was reduced by stimulation of heat shock proteins (Takahashi et al., 2015; Nakazono et al., 2018). Aggregates of endogenous mutant PKCy have also been detected in SCA14 patient-derived iPSCs (Seki et al., 2009; Wong et al., 2018). However, the interplay between altered PKCy activity and aggregation has yet to be elucidated. Thus, whereas the aforementioned previous studies have proposed a variety of mechanisms that may be involved in the cerebellar degeneration that is characteristic of ataxia, the previously established correlation between enhanced basal activity of PKCy variants with age of disease onset support a model in which increased PKCy signaling in the absence of second messengers likely drives SCA14 (Pilo et al., 2022).

Mouse models of ataxia generated by Kapfhammer and others have demonstrated that PKCy mutations drive SCA14 pathogenesis (Ji et al., 2014; Trzesniewski et al., 2019; Shimobayashi and Kapfhammer, 2021). The first of these mouse models was the S361G transgenic mouse, which was shown to exhibit an ataxic...
phenotype and reduction of PC surface area (Ji et al., 2014). They also generated a transgenic mouse expressing a pseudosubstrate mutant PKCy, A24E, which caused an ataxic phenotype and weakened PC development (Shimobayashi and Kapfhammer, 2021). Mutations in the pseudosubstrate generally decrease its affinity for the active site, thus destabilizing PKC (Baffi et al., 2019). Although the A24E mutation reduced PKCy stability, the basal activity of the A24E mutant PKCy increased cerebellar substrate phosphorylation and was sufficient to drive an ataxic phenotype. Thus, these mouse models have supported the idea that increased PKCy activity may be a main driver of SCA14 pathology.

REFERENCES

Abrahamsen, H., O’Neill, A. K., Kannan, N., Kruse, N., Taylor, S. S., Jennings, P. A., et al. (2012). Peptidyl-prolyl Isomerase Pin1 Controls Down-Regulation of Conventional Protein Kinase C Isozymes. J. Biol. Chem. 287, 13262–13278. doi:10.1074/jbc.M112.409753

Adachi, N., Kobayashi, T., Takahashi, H., Kawasaki, T., Shirai, Y., Ueyama, T., et al. (2008). Enzymological Analysis of Mutant Protein Kinase Cγ Causing Spinocerebellar Ataxia Type 14 and Dysfunction in Ca2+ Homeostasis. J. Biol. Chem. 283, 19854–19863. doi:10.1074/jbc.M801492200

Alothaim, T., Charbonneau, M., and Tang, X. (2021). HDAC6 Inhibitors Sensitize Non-mesenchymal Triple-Negative Breast Cancer Cells to Cysteine Deprivation. Sci. Rep. 11, 10956. doi:10.1038/s41598-021-90527-6

CONCLUSION

PKCy is best understood in the context of the neurodegenerative disorder, SCA14, however, many gaps in our knowledge of this PKC isozyme remain. Despite belonging to the generally well-studied group of conventional PKC isozymes, limited attention has been given to the aberrant expression of PKCy in colon cancer, in particular. Furthermore, whereas several studies have reported that knockdown of this enzyme in cancer cells inhibited proliferation and foci formation in 3D, many of these cancer cell lines have somatic mutations in PKCy that were not addressed. Given that PKC mutations in cancer generally are not only loss of function, but also dominant-negative, gaining a better understanding of cancer-associated PKCy mutations will be critically important to applying therapies that will produce beneficial outcomes in cancer patients harboring these mutations (Figure 2). Gaps also exist in our understanding of the role of PKCy in SCA14. Although mechanistic studies converge on enhanced PKC basal activity driving SCA14 pathogenesis, how this leaky activity leads to PC degeneration remains to be established (Figure 2). Elucidation of the structure for PKCy will also greatly advance our understanding of this isozyme. Although the theoretical models and partial crystal structures that have been generated are currently helpful tools in predicting mutational effects, these are based on the better-characterized PKCβII. Despite many PKC isozymes sharing a common 3D architecture, the subtle primary sequence differences as well as the highly variable C-tail likely alter factors such as interdomain interactions, subcellular localization, and substrate preferences. The impact disease-specific mutations have on these factors for PKCy, specifically, will be difficult to fully grasp until a structure is fully solved.

AUTHOR CONTRIBUTIONS

CP and AN wrote the manuscript.

FUNDING

This work was supported by NIH R35 GM122523 and NIH 1R01NS120725. CP was supported in part by the UCSD Graduate Training Program in Cellular and Molecular Pharmacology (T32 GM007752).

ACKNOWLEDGMENTS

We thank members of the Newton Lab for helpful comments.
Saito, N., Kikkawa, U., Nishizuka, Y., and Tanaka, C. (1988). Distribution of Protein Kinase C-like Immunoreactive Neurons in Rat Brain. J. Neurosci. 8, 369–382. doi:10.1523/jneurosci.08-02-00369.1988

Saito, N., and Shirai, Y. (2002). Protein Kinase C (PKC): Function of Neuron Specific Isoform. J. Biochem. 132, 683–687. doi:10.1093/oxfordjournals.jbchem.a003274

Schmitz-Hübsch, T., Lux, S., Bauer, P., Brandt, A. U., Schlapakow, E., Greschus, S., et al. (2021). Spinocebellar Ataxia Type 14: Refining ClinicoGenetic Diagnosis in a Rare Adult-onset Disorder. Ann. Clin. Transl. Neurol. 8, 774–789. doi:10.1002/acn3.51315

Schenk, K., Kapfhammer, J. P., and Metzger, F. (2002). Altered Dendritic Development of Cerebellar Purkinje Cells in Slice Cultures from Protein Kinase C-Deficient Mice. Neuroscience 110, 675–689. doi:10.1016/S0306-4522(01)00359-0

Seki, T., Shimahara, T., Yamamoto, K., Abe, N., Amano, T., Adachi, N., et al. (2009). Mutant yPKC Found in Spinocebellar Ataxia Type 14 Induces Aggregate-independent Maldevelopment of Dendrites in Primary Cultured Purkinje Cells. Neurobiol. Dis. 33, 260–273. doi:10.1016/j.nbd.2008.10.013

Shimobayashi, E., and Kapfhammer, J. P. (2017). Increased Biological Activity of Mutant PKC in Spinocerebellar Ataxia Type 14 Disrupts Synapse Elimination and Long-Term Depression in Purkinje Cells In Vivo. J. Neurosci. 37, 14324–14334. doi:10.1523/JNEUROSCI.3041-17-0133-2

Shirafuji, T., Shimazaki, H., Miyagi, T., Ueyama, T., Adachi, N., Tanaka, S., et al. (2019). Spinocebellar Ataxia Type 14 Caused by a Nonsense Mutation in the PRKCG Gene. Mol. Cell. Neurosci. 98, 46–53. doi:10.1016/j.mcneu.2019.05.005

Shuvaev, A. N., Horiuichi, H., Seki, T., Goenawan, H., Irie, T., Iizuka, A., et al. (2011). Mutant PKC in Spinocebellar Ataxia Type 14 Disrupts Normal Morphology and Function of the Cerebellar Cortex in a Mouse Model of Spinocerebellar Ataxia. Exp. Neurol. 311, 205–212. doi:10.1016/j.expneurol.2018.10.004

Takahashi, H., Adachi, N., Shirafuji, T., Danno, S., Ueyama, T., Vendruscolo, M., et al. (2015). Identification and Characterization of PKCσ, a Kinase Associated with SCA14, as an Amyloidogenic Protein. Hum. Mol. Genet. 24, 525–539. doi:10.1093/hmg/ddu472

Tovell, H., and Newton, A. C. (2021). PHLPPing the Balance: Restoration of Protein Kinase C in Cancer. Biochem. J. 478, 341–355. doi:10.1042/BCJ20190765

Trzesniewski, J., Altmann, S., Jäger, L., and Kapfhammer, J. P. (2019). Reduced Purkinje Cell Size Is Compatible with Near Normal Morphology and Function of the Cerebellar Cortex in a Mouse Model of Spinocerebellar Ataxia. Exp. Neurol. 311, 205–212. doi:10.1016/j.expneurol.2018.10.004

Tsumagari, R., Kakizawa, S., Kikunaga, S., Fujihara, Y., Ueda, S., Yamanoue, M., et al. (2020). DKGK Knock-Out Mice Show Impairments in Cerebellar Motor Coordination, LTD, and the Dendritic Development of Purkinje Cells through the Activation of PKCγ. eNeuro 7, 0319–19. doi:10.1523/EJNNEURO.0319-19.2020

Van, A.-A. N., Kunkel, M. T., Baffi, T. R., Lordén, G., Antal, C. E., Banerjee, S., et al. (2021). Protein Kinase C Fusion Proteins Are Paradoxically Loss of Function in Cancer. J. Biol. Chem. 296, 100445–100518. doi:10.1016/j.jbc.2021.100445

Verbeek, D. S., Goodhart, J., Bruinsma, L., Sinke, R. J., and Reits, E. A. (2008). PKCy Mutations in Spinocerebellar Ataxia Type 14 Affect Cl Domain Accessibility and Kinase Activity Leading to Aberrant MAPK Signaling. J. Cell. Sci. 121, 2339–2349. doi:10.1242/jcs.027698

Verbeek, D. S., Knight, M. A., Harmison, G. G., Fischbeck, K. H., and Howell, B. W. (2005). Protein Kinase C Gamma Mutations in Spinocerebellar Ataxia 14 Increase Kinase Activity and Alter Membrane Targeting. Brain 128, 436–442. doi:10.1093/brain/awh378

Violin, J. D., Zhang, J., Tsien, R. Y., and Newton, A. C. (2003). A Genetically Encoded Fluorescent Reporter Reveals Oscillatory Phosphorylation by Protein Kinase C. J. Cell. Biol. 161, 899–909. doi:10.1083/jcb.200302125

Wong, M. M. K., Hockstra, S. D., Vowles, J., Watson, L. M., Fuller, G., Németh, A. H., et al. (2018). Neurodegeneration in SCA14 Is Associated with Increased PKCy Kinase Activity, Mislocalization and Aggregation. acta neuropathol. Commun. 6, 99. doi:10.1186/s40478-018-0600-7

Yabe, I., Sasaki, H., Chen, D.-H., Raskind, W. H., Bird, T. D., Yamashita, I., et al. (2003). Spinocerebellar Ataxia Type 14 Caused by a Mutation in Protein Kinase Cγ. Arch. Neurol. 60, 1749–1751. doi:10.1001/archneur.60.12.1749

Yamaguchi, Y., Shirai, Y., Matsubara, T., Sanse, K., Kuriyama, M., Oshiro, N., et al. (2006). Phosphorylation and Up-Regulation of Diacylglycerol Kinase γ via its Interaction with Protein Kinase Cy. J. Biol. Chem. 281, 31627–31637. doi:10.1074/jbc.M60699220010.1016/s0021-9258(19)80476-0

Yamashita, I., Sasaki, H., Yabe, I., Fukazawa, T., Nogoshi, S., Komeichi, K., et al. (2000). A Novel Locus for Dominant Cerebellar Ataxia (SCA14) Maps to a 10.2-cM Interval Flanked by D19S206 and D19S605 on Chromosome 19q13.4-qter. Ann. Neurol. 48, 156–163. doi:10.1002/1531-8249(200008)48:2<156::AID-ANA4>3.0.CO;2-9

Yang, Y., and Igunenova, T. I. (2013). The C-Terminal V5 Domain of Protein Kinase Ca Is Intrinsically Disordered, with Propensity to Associate with a Membrane Mimetic. PLoS ONE 8, e56599. doi:10.1371/journal.pone.0056599

Zhang, L. L., Cao, F. F., Wang, Y., Meng, F. L., Zhang, Y., Zhong, D. S., et al. (2015). The Protein Kinase C (PKC) Inhibitors Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials. Clin. Transl. Oncol. 17, 371–377. doi:10.1007/s12994-014-1241-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pilo and Newton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.